{
  "id": 5331977,
  "title": "UK MedTech Strolll secures €5 million in Innovate UK funding and additional IW Capital-led investment",
  "url": "https://urgent.news/2026/09/03/uk-medtech-strolll-secures-5-million-in-innovate-uk-funding-and",
  "topic": "tech",
  "section": "Tech",
  "published": "2026-09-03T12:37:54.000Z",
  "source": {
    "name": "EU-Startups",
    "slug": "eu-startups",
    "url": "https://www.eu-startups.com/2026/09/uk-medtech-strolll-secures-e5-million-in-innovate-uk-funding-and-additional-iw-capital-led-investment/"
  },
  "original_language": "en",
  "account": "Strolll, a Stafford-based augmented reality (AR) software-as-a-medical-device (SaMD) company specializing in neurorehabilitation, has secured a substantial €5 million investment. This funding, led by IW Capital, includes a €4.18 million (£3.6 million) innovation loan from Innovate UK and an €813.2k (£700k) Growth Catalyst Investor Partnerships (GCIP) award. The total funding from these two sources amounts to €5 million (£4.3 million) and is earmarked for two separate projects.\n\nCEO and co-founder Jorgen Ellis expressed enthusiasm about the investment, stating that the team is dedicated to revolutionizing rehabilitation for individuals with neurological disorders. He emphasized that the funds will aid in increasing patient engagement, supporting progression, and enabling clinicians to deliver effective neurorehabilitation to a broader patient population.\n\nFounded in 2018, Strolll develops digital therapeutics software that operates through AR glasses, providing clinically validated and patented neurorehabilitation to patients with neurological conditions. The software supports therapy in both clinical and home settings. The neurorehabilitation market is expanding due to the increasing demand for rehabilitation services and ongoing support, a need Strolll aims to address with its AR-based approach.\n\nThe €4.18 million (£3.6 million) Innovate UK loan is intended to expedite the development of StrolllAssessment, a platform that integrates AI with a comprehensive biomechanics lab. This lab replicates real-world rehabilitation environments, enabling multiple validation studies to occur simultaneously, thereby reducing a process that typically takes years to just months. The loan also supports the creation of a fully equipped biomechanics lab at Strolll's Stafford office, designed to simulate real-world rehabilitation settings and facilitate the simultaneous validation of numerous digital assessments.\n\nThe €813.2k (£700k) GCIP award, combined with over £1 million (£1.16 million) in investor funding, will be used to launch StrolllAcute, a bedside-first AR rehabilitation system tailored for acute, bed-bound patients. This system allows for early therapeutic intervention without disrupting existing ward workflows or increasing staff workload. Scott O'Brien, Chief Investment Officer at Innovate UK, highlighted that Strolll received investment due to its technical excellence and promising path to commercial success. He noted that the £4.18 million innovation loan from Innovate UK, alongside grant funding from private capital, underscores Innovate UK's commitment to supporting innovations at critical stages to accelerate growth.",
  "summary": "Strolll, a Stafford-based software-as-a-medical-device (SaMD) company using Augmented Reality for neurorehabilitation, has secured a new round of investment led by IW Capital, with participation from Cleveland Clinic and Future Planet Capital Regional. Additionally, Innovate UK has separately provided the company with a €4.18 million (£3.6 million) innovation loan and an €813.2k (£700k) Growth…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}